Compare Cassava Sciences Inc (FLNA) vs Freshworks Inc (FRSH) Price & Performance

FLNA trades at $0.8136, down 0.26% with a bearish technical signal. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent positive FDA news regarding the clinical hold lift on simufilam for epilepsy research provides a potential catalyst. Cash flow remains negative with net cash flow of -$33.07M in 2025.

The outlook is mixed with strong analyst support (66.7% buy ratings) against fundamental challenges. Investment opportunity lies in clinical trial success, while risks include sustained cash burn and execution hurdles. The stock's low EV/EBITDA of 1.03 and P/B of 0.62 suggest undervaluation if pipeline milestones are met.

Freshworks (FRSH) trades at $13.64, up 0.29% with strong technical momentum showing bullish moving average signals. The company achieved its first GAAP profitability in Q2 2026 with revenue growth of 16% year-over-year, beating earnings expectations. Recent developments include FedRAMP certification progress and leadership in Gartner's ITSM Magic Quadrant, positioning the company for enterprise growth.

FRSH presents a compelling investment case with attractive valuation metrics (P/E 21.63, P/S 4.28) and strong profitability margins (84.96% gross margin, 20.49% net margin). However, elevated EV/EBITDA (43.89) and competitive SaaS market pressures require monitoring. Analyst consensus is evenly split between Buy and Hold with $14.60 price target suggesting modest upside potential from current levels.